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Abstract
Ketoconazole is a broad-spectrum antifungal agent, which has recently been characterized as a potential anticancer agent in several cancer types. However, the molecular mechanism underlying the anticancer effect of ketoconazole is not clearly defined. Our recent findings demonstrate that ketoconazole suppresses the growth of hepatocellular carcinoma (HCC) cells by exacerbating mitophagy in vitro and in vivo. Mechanistically, PINK1-PRKNmediated mitophagy are led by ketoconazole-induced suppression of PTGS2 (prostaglandinendoperoxide synthase 2), which in turn results in mitochondrial dysfunction and consequent apoptosis. These data link PTGS2 to mitophagy machinery and implicate ketoconazole as a potential therapeutic option for HCC treatment.
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Ketoconazole is a broad-spectrum antifungal agent and is primarily used to treat fungal infections. The use of ketoconazole oral tablets for fungal infections has been limited due to potential risk of liver injury. However, growing evidence suggests that ketoconazole alone or in combination with other agents exhibits promising anticancer activity against multiple cancers including glioblastoma, prostate, breast, colon, and bladder cancers. Recently, we demonstrated that ketoconazole suppresses hepatocellular carcinoma (HCC) cell growth by eliciting apoptosis, with no obvious effects on human liver cells [1] . The antitumor effects of ketoconazole in HCC was further confirmed in both a cell line-derived xenograft model and patient-derived xenograft model, supporting the idea of ketoconazole as a potential anticancer agent for HCC treatment.
To ascertain the mechanism underlying the antitumor effect of ketoconazole, we examined whether ketoconazole induced mitochondrial dysfunction, which has been noted as a common consequence of azole antifungal drugs. Consistent with prior studies, massive mitochondrial fragmentation and loss are observed in HCC cells in response to ketoconazole treatment. Because mitophagy, a cargo-specific form of autophagy, has been recognized as a main form of mitochondrial quality control to remove dysfunctional mitochondria, we investigated whether ketoconazole induced mitophagy in HCC cells and confirmed the occurrence of mitophagy. Interestingly, inhibiting mitophagy suppresses ketoconazoleinduced mitochondrial dysfunction and apoptotic cell death, which contradicts the paradigm that mitophagy maintains mitochondrial dynamics.
Mitophagy is critical for maintaining cellular homeostasis and is proposed to protect cells from accumulated mitochondrial damage. To date, the induction of mitophagy is mainly attributed to the PINK1-PRKN axis, both of which are involved in Parkinson disease.
A c c e p t e d M a n u s c r i p t Mechanistically, PINK1 accumulates on the outer membrane of damaged mitochondria and recruits PRKN from the cytosol, which then ubiquitinates mitochondrial proteins to mark damaged mitochondria for disposal via the autophagy pathway. Indeed, we found that ketoconazole induces complete mitophagy in a PINK1-PRKN-dependent manner in HCC cells. However, a causal relationship between mitophagy and mitochondrial dysfunction is observed, indicating that mitophagy may determine cell fate in a context-dependent manner.
Despite the initially recognized protective role for mitophagy in mitochondrial metabolism, several functionally distinct variants of mitophagy have been described recently; each may lead to cell death in an apoptosis-dependent or -independent manner. These previous studies confirm the lethal consequences of mitophagy, but the upstream mechanism leading to the variation of mitophagy, especially on the involved regulatory network in cancer cells, remains largely unknown. It is thus of interest to further investigate the mechanism by which mitophagy is induced and exacerbated in cancer cells.
In our study, ketoconazole-induced mitophagy in HCC cells is mediated by the downregulation of PTGS2/COX-2 (prostaglandin-endoperoxide synthase 2), a key enzyme catalyzing the conversion of arachidonic acid into prostaglandins. Enforced expression of PTGS2 prevents mitophagy-mediated mitochondrial dysfunction by impeding PINK1 accumulation and PRKN recruitment on mitochondrial membrane in ketoconazole-treated HCC cells, supporting the concept of PTGS2 as a negative regulator of mitophagy induction.
These results, in conjunction with the causal role of ketoconazole-induced mitophagy in mitochondria loss, suggest that PTGS2-mediated mitophagy not only occurs in damaged mitochondria but also is incurred by healthy mitochondria. Together, these data revealed a novel role for PTGS2 in mitophagy induction, which may eventually result in mitochondria dysfunction via a vicious cascade including massive mitochondria loss and mitochondrial 
